Growing demand from molecular diagnostics, biopharmaceutical, and academic institutions and customers compounds growth opportunities, finds Frost & Sullivan’s Transformational Health team

Santa Clara, Calif. – August 29, 2017

The United States (U.S.) next-generation sequencing (NGS) informatics market is witnessing double-digit growth, supported by the increasing demand from molecular diagnostics, biopharmaceutical, and academic institution customers. Pharmaceutical companies’ strong focus on developing precision and personalized therapies, the launch of large-scale genome sequencing projects, and expected reimbursement and approval policy developments for NGS-based diagnostic tests will augment the requirement for NGS informatics solutions.

Frost & Sullivan’s market research, “Transformation and Growth Opportunities in the US Next-generation Sequencing Informatics Market, Forecast to 2021,” finds that the U.S. NGS informatics market generated revenues of $416 million in 2016 and is expected to register a compound annual growth rate (CAGR) of 19.0 percent through 2021.

“End-to-end informatics solutions focused on clinical applications is the greatest unmet need of customers,” explained Transformational Health Senior Industry Analyst Piyush Bansal. “Researchers’ reluctance to move onto external platforms due to the lack of end-to-end informatics tools and limited availability of a clinical application-focused analysis pipeline is a key industry challenge. Overcoming this challenge will be critical to success.”

Several trends and developments bolster the U.S. NGS informatics market:

  • Intense merger and acquisition activities from companies such as Illumina, Qiagen, and Roche to develop unique end-to-end products and solutions;
  • Strategic alliances, partnerships, and collaborations to enhance NGS bioinformatics capabilities and offer integrated, interoperable solutions to their clients;
  • High adoption of cloud-based solutions to support ever-increasing high-end data storage client requirements, with public and private cloud solutions integrated into service offerings;
  • Growing focus on developing informatics products for precision medicine and molecular diagnostics companies;
  • Inclusion of multi-omics data for interpretation;
  • Developing big data analytics in clinical interpretation;
  • Strong demand for high-speed computation and data analysis tools due to launch of high-throughput sequencing equipment and population-scale genome sequencing;
  • Move from core informatics solutions toward sequencing-to-report offerings with informatics platforms integrated with sequencing equipment in the long term;
  • Support for public sequencing projects to develop focused expertise; and
  • Emergence of strong business models like software-as-a-service (SAAS), with large companies focusing on DNA sample-to-clinical report capabilities.

“The expected entry of big data information technology companies will integrate healthcare (such as EHR and imaging data) and genomics data to develop and provide artificial intelligence (AI)-based computation and interpretation solutions,” noted Bansal. “This will intensify market competition and force smaller players to innovate as clinical interpretation and reporting capabilities become key differentiators among service providers.”

Source: Frost & Sullivan

Illustration Photo: Prenatal Genome Sequencing (credits: Ernesto del Aguila III, NHGRI / Flickr Creative Commons Attribution-NonCommercial 2.0 Generic (CC BY-NC 2.0))

Comments

No comments to display.